Active, not recruitingPhase 2NCT06284954
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
Studying Dermatomyositis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- argenx
- Intervention
- Empasiprubart IV(biological)
- Enrollment
- 3 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (28)
- Profound Research LLC, Oceanside, California, United States
- Omega Research Debary, LLC, DeBary, Florida, United States
- University of Florida Health (UF) - Endocrinology - Medical Specialties - Medical Plaza, Gainesville, Florida, United States
- Homestead Associates in Research, Inc., Homestead, Florida, United States
- Life Clinical Trials, Margate, Florida, United States
- Advance Medical Research Center, Miami, Florida, United States
- Integral Rheumatology and Immunology Specialists (IRIS), Plantation, Florida, United States
- D and H Tamarac Research, LLC Center, Tamarac, Florida, United States
- Wright State Physicians Health Center, Dayton, Ohio, United States
- V.Tsitlanadze Scientific Practical Reumatology Center, Tbilisi, Georgia
- The First University Clinic of Tbilisi State Medical University, Tbilisi, Georgia
- Institute of Clinical Cardiology, Ltd, Tbilisi, Georgia
- Jerarsi Clinic, Tbilisi, Georgia
- Mtskheta street Clinic, Tbilisi, Georgia
- The First Medical Center, Tbilisi, Georgia
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06284954 on ClinicalTrials.govOther trials for Dermatomyositis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07111065FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)National Institute of Environmental Health Sciences (NIEHS)
- ACTIVE NOT RECRUITINGNCT07531446Construction of a Clinico-Imaging Collaborative Diagnostic Model for Dermatomyositis Combined With Interstitial Lung Disease Based on PET/CT Imaging Features and Clinical ParametersRuijin Hospital
- RECRUITINGPHASE2, PHASE3NCT07160205Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)Restem, LLC.
- RECRUITINGNANCT07377058RCT of Tocilizumab for Anti-MDA5+DMPeking Union Medical College Hospital
- RECRUITINGNCT07345949Panniculitis in DermatomyositisUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE2NCT06857240Topical Ruxolitinib Cream for Refractory Cutaneous DermatomyositisThe Cleveland Clinic
- RECRUITINGPHASE1NCT06919380Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy TrialLi Shiyue
- RECRUITINGPHASE2NCT06672822Intralesional Injection of STS in Treatment of CalcinosisRobyn T. Domsic, MD, MPH